Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,226 matching trials from the live ClinicalTrials.gov search.
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Bone Marrow Transplantation Recipient, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Laboratory Biomarker Analysis, Placebo
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Conditions
Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
Interventions
Varicella Zoster Vaccine, Placebo Injection
Biological · Other
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
5
States / cities
Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
Conditions
Hyperbilirubinemia, Neonatal
Interventions
Stannsoporfin, Placebo, PhotoTherapy (as needed)
Drug · Other
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Minute to 48 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Colton, California • San Diego, California • Honolulu, Hawaii + 5 more
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

NCT06564194
Conditions
Respiratory Syncytial Virus (RSV), Infectious Disease
Interventions
JCXH-108, Placebo
Biological · Other
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Jupiter, Florida • New Orleans, Louisiana • St Louis, Missouri
Conditions
SARS-CoV-2 Infection
Interventions
25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Biological · Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Itraconazole, Flucytosine, Fluconazole, Amphotericin B, Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Camden, New Jersey + 3 more
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Conditions
Steatohepatitis, Nonalcoholic
Interventions
ION224, Placebo
Drug · Other
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
50
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 43 more
Conditions
Spinal Cord Injury, Pain
Interventions
botulinum toxin A, placebo
Drug · Other
Lead sponsor
Craig Hospital
Other
Eligibility
15 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Englewood, Colorado
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of STAR-0310 in Healthy Adult Participants

NCT06782477
Conditions
Healthy Participants
Interventions
STAR-0310, Placebo
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Homewood, Alabama • Los Angeles, California • Orange, California + 24 more
Conditions
Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Simtuzumab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 34 more
Conditions
Acute Coronary Syndrome
Interventions
Placebo, CER-001
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
Up to 75 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 21 more
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Obesity in Women Via Estradiol Regulation

NCT00687739
Conditions
Obesity
Interventions
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
HCG
Interventions
Human Chorionic Gonadotropin, Placebo, Low calorie diet
Drug · Other
Lead sponsor
Dr. Emma's Corporation
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Colts Neck, New Jersey
Conditions
Meniscus Tear
Interventions
AM3101, Saline Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
30
States / cities
Fort Smith, Arkansas • Beverly Hills, California • Encinitas, California + 26 more
Conditions
Aging
Interventions
Testosterone, Protein Supplement, Placebo Injection, Placebo supplement
Drug · Dietary Supplement · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

NCT01357421
Conditions
Traumatic Brain Injury
Interventions
TT301, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Ebola Disease, Immunisation
Interventions
ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Femoral Neck Fractures, Hip Fractures
Interventions
Femoral nerve block: 25 mL of 0.5% bupivacaine, Placebo: 3cc of 0.9% Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
55 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Terminated Not applicable Interventional Results available

Use of Teriparatide to Accelerate Fracture Healing

NCT00594906
Conditions
Pelvic Fracture
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, New York